Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors

Johnson, Douglas S, Weerapana, Eranthie, Cravatt, Benjamin F·2010·Future Medicinal Chemistry
DOI 10.4155/fmc.10.21

Cited by (425)

Items 301–400 of 425

  1. ARCaDia: single-round screening of a DNA-type targeted covalent binder possessing a latent warhead
    Masumi Taki, Masayasu Kuwahara, Chaohui Li, Naoko Tomoda, Naoyuki Miyashita, Tetsuo Kan, Jay Yang · 2024 · Chemical Communications
  2. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network
    Zhihao Gu, Yong Jie Yan, Hanwen Liu, Di Wu, Hequan Yao, Kejiang Lin, Xuanyi Li · 2024 · Journal of Chemical Information and Modeling
  3. An Unbiased Immunoaffinity-Based Strategy for Profiling Covalent Drug Targets In Vivo
    Xinyuan Wang, Xiuxuan Wang, Xinghua Pu, Wenchen Pu, Yuqi Wang, Yu Liu, Yanqiu Gong, Xiuxiu Jin, Yong Peng, Lunzhi Dai · 2019 · Analytical Chemistry
  4. Distinguishing the optimal binding mechanism through reversible and irreversible inhibition analysis of HSP72 protein in cancer therapy
    Aimen Aljoundi, Ahmed Abd Elkader El-Rashedy, Mahmoud E. S. Soliman · 2021 · Computers in Biology and Medicine
  5. Detection of an enzyme isomechanism by means of the kinetics of covalent inhibition
    Suara A. Adediran, Michael J. Morrison, Rex F. Pratt · 2021 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  6. Characterization of an agonist probe for opioid receptor mu 1 (OPRM1)-opioid receptor delta 1 (OPRD1) heterodimerization
    Christie E. Pinello, Miguel A. Guerrero, Christina Eberhart, Claude‐Henry Volmar, Sanjay Adrian Saldanha, Charmagne S. Cayanan, Mariagela Urbano, Steven J Brown, Jill Ferguson, Ivone Gomes et al. · 2013
  7. Reactive Electrophiles and Metabolic Activation
    Ronald Scott Obach, Amit S.S. Kalgutkar · 2017 · Elsevier eBooks
  8. Optimization and characterization of a triazole urea inhibitor for alpha/beta hydrolase domain-containing protein 11 (ABHD11): anti-probe for LYPLA1/LYPLA2 dual inhibitor ML211
    Alexander Adibekian, Ku‐Lung Hsu, Anna E Speers, Steven J Brown, Timothy Spicer, Virneliz Fernández-Vega, Jill Ferguson, Benjamin F. Cravatt, Peter Hodder, Hugh Rosen · 2013 · Europe PMC (PubMed Central)
  9. Structure–activity relationship studies on 1-heteroaryl-3-phenoxypropan-2-ones acting as inhibitors of cytosolic phospholipase A2αand fatty acid amide hydrolase: replacement of the activated ketone group by other serine traps
    Tom Richard Sundermann, Walburga Hanekamp, Matthias Lehr · 2015 · Journal of Enzyme Inhibition and Medicinal Chemistry
  10. Quantitative proteomics in development of disease protein biomarkers
    Lei Wang, Adam J. McShane, Mary Joan Castillo, Xudong Yao · 2019 · Elsevier eBooks
  11. Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1-[(dimethylamino)methyl]-2-naphthol at 4 hours of soaking
    F. Angelucci, I. Silvestri, Francesca Fata, D.L. Williams · 2019 · Worldwide Protein Data Bank
  12. The Cathepsin Family in Disease: From Molecular Mechanisms to Therapeutic Applications
    Lorca Alzoubi, Yassmen Hamzat, A. Alqudah, Alaa A. A. Aljabali · 2025 · Current Neuropharmacology
  13. From Transient to Stable: Incorporating Electrophiles in Genetically-Encoded and DNA-Encoded Libraries of Peptide-Derived Macrocycles
    James C. Walker, Kejia Yan, Ratmir Derda · 2026 · Biochemistry
  14. Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-Like KRAS G12C Inhibitors
    Alexandra Frommlet, Lan K. Nguyen, Matt Saabye, Nicholas Endres, Melinda M. Mulvihill, John G. Quinn · 2024 · ACS Omega
  15. A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
    Rachel M. Sammons, Kevin N. Dalby · 2020 · Springer eBooks
  16. Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
    Sanfeng Dong, Hui Yu Huang, Jintian Li, Xiaomei Li, Samuel J. Bunu, Yun Yang, Yong Zhang, Qi Jia, Zhijian Xu, Yingxia Li et al. · 2024 · Communications Chemistry
  17. Optimization and characterization of a triazole urea inhibitor for platelet-activating factor acetylhydrolase type 2 (PAFAH2)
    Alexander Adibekian, Ku‐Lung Hsu, Anna E Speers, Elizabeth S Monillas, Steven J Brown, Timothy Spicer, Virneliz Fernández-Vega, Jill Ferguson, Brian J. Bahnson, Benjamin F. Cravatt et al. · 2013 · Europe PMC (PubMed Central)
  18. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations
    Fereshteh Noroozi Tiyoula, Hassan Aryapour · 2022 · PLoS ONE
  19. A mathematically rigorous algorithm to define, compute and assess relevance of the probable dissociation constants in characterizing a biochemical network
    Siddhartha Kundu · 2024 · Scientific Reports
  20. Hit-to-lead optimization of amino-carboxamide benzothiazoles as LSD1 inhibitors
    Du’a Al bustanji, Soraya Alnabulsi, Enas A. Al-Hurani · 2023 · Medicinal Chemistry Research
  21. Molecular Docking
    Bharathi Sundaram, Sumeer Ahmed · 2025 · IGI Global eBooks
  22. An Enzyme-Catalyzed Polymerization Strategy Disrupts Protein Homeostasis for Improved Tumor Therapy
    Yinsheng Xu, Yingjin Zhang, Benli Song, Yixuan Liu, Yi Hao, Duan Zhongyu, Zeng‐Ying Qiao, Hao Wang · 2025 · Biomacromolecules
  23. Probe Development Efforts to Identify Novel Inhibitors of ABHD10
    Andrea M. Zuhl, Justin T. Mohr, Anna E Speers, Daniel A. Bachovchin, Jacob M. Berlin, Timothy Spicer, Virneliz Fernández-Vega, Steven J Brown, Jill Ferguson, Greg C Fu et al. · 2013 · Europe PMC (PubMed Central)
  24. Covalent drugs in development for immune-mediated diseases
    Leonard Sung · 2021 · Annual reports in medicinal chemistry
  25. High-Throughput Discovery and Characterization of Covalent Inhibitors for Protein Tyrosine Phosphatases
    Zihan Qu, Aaron D. Krabill, Zhong‐Yin Zhang · 2023 · Methods in molecular biology
  26. Reactive Electrophiles and Metabolic Activation
    Ronald Scott Obach, Amit S.S. Kalgutkar · 2024 · Elsevier eBooks
  27. Covalent inhibitors in Parkinson's disease: Molecular targeting strategies for neuroprotective intervention
    Devadharuna Mohan, Raghul Venkatesan, Amarjith Thiyyar Kandy, Santhoshkumar Muthu, J. Saravanan, Rajinikanth Baskaran, Palanisamy Pethappachetty, Divakar Selvaraj · 2025 · Molecular and Cellular Neuroscience
  28. A simple and widely applicable hit validation strategy for protein–protein interaction inhibitors based on a quantitative ligand displacement assay
    Tomoya Sameshima, Ikuo Miyahisa, Misaki Homma, Katsuji Aikawa, Mark S. Hixon, Junji Matsui · 2014 · Bioorganic & Medicinal Chemistry Letters
  29. SSPaQ: A Subtractive Segmentation Approach for the Exhaustive Parallel Quantification of the Extent of Protein Modification at Every Possible Site
    Guillaume Gabant, Alain Boyer, Martine Cadène · 2016 · Journal of the American Society for Mass Spectrometry
  30. An in Vivo Active Carbamate-based Dual Inhibitor of Lysophospholipase 1 (LYPLA1) and Lysophospholipase 2 (LYPLA2)
    Jonathan J. Hulce, Christopher M. Joslyn, Anna E Speers, Steven J Brown, Timothy Spicer, Virneliz Fernández-Vega, Jill Ferguson, Benjamin F. Cravatt, Peter Hodder, Hugh Rosen · 2014 · Europe PMC (PubMed Central)
  31. Medicinal Chemistry Case History: Osimertinib (AZD9291)
    Richard A. Ward, M. Raymond V. Finlay · 2016 · Elsevier eBooks
  32. The art of suicidal molecular seduction for targeting drug resistance
    Mohammad Hassan Moshafi, Saeid Ghasemshirazi, Ardavan Abiri · 2020 · Medical Hypotheses
  33. COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT
    Shujaath Mehdi · 2013 · Wiley eBooks
  34. Non-equilibrium modalities of inhibition: Characterizing irreversible inhibition for the ErbB receptor family members
    Bharath Srinivasan · 2023 · Methods in enzymology on CD-ROM/Methods in enzymology
  35. The synthesis of possible transition state analogue inhibitors of thymidine phosphorylase
    Gary B. Evans, Graeme J. Gainsford, Vern L. Schramm, Peter C. Tyler · 2014 · Tetrahedron Letters
  36. Probe Development Efforts to Identify Novel Inhibitors of Protein Phosphatase Methylesterase-1 (PME-1)
    DA Bachovchin, AE Speers, SJ Brown, Timothy P. Spicer, Fernandez-Vega, J Ferguson, Justin T. Mohr, James M. Murphy, Gregory C. Fu, BF Cravatt et al. · 2011 · Europe PMC (PubMed Central)
  37. Optimization and characterization of a carbamate inhibitor for plasma platelet-activating factor acetylhydrolase (pPAFAH)
    Joseph M G Nagano, Ku‐Lung Hsu, Anna E Speers, Steven J Brown, Timothy Spicer, Virneliz Fernández-Vega, Jill Ferguson, Brian J. Bahnson, Benjamin F. Cravatt, Peter Hodder et al. · 2014 · Europe PMC (PubMed Central)
  38. Molecular Dynamics, Quantum Mechanics, and Combined Quantum Mechanics/Molecular Mechanics Methods for Drug Discovery and Development
    Eric J. M. Lang, Adrian John Mulholland · 2017 · Elsevier eBooks
  39. Computational support of structure-based targeted covalent inhibitor design
    Robert Abel, Richard A. Friesner · 2021 · Annual reports in medicinal chemistry
  40. Synthesis in Medicinal Chemistry
    Allan Michael Jordan, Robert J. Young · 2023 · Royal Society of Chemistry eBooks
  41. Mitigating Toxicity Risks with Affinity Labeling Drug Candidates
    Amit S.S. Kalgutkar, Deepak Dalvie, Ronald Scott Obach, Dennis A. Smith · 2012 · Methods and principles in medicinal chemistry
  42. Control of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase
    James Harry Long · 2012
  43. Message from the Editors
    Gino D’Oca, Isaac Bruce · 2012 · Future Medicinal Chemistry
  44. Targeted Covalent Inhibition of Telomerase
    Rick C. Betori, Yue Liu, Ding Wu, Rama K. Mishra, Scott Cohen, Stephen J. Kron, Karl A. Scheidt · 2019 · ChemRxiv
  45. Tryptoline Stereoprobe Elaboration Identifies Inhibitors of the GRPEL1-HSPA9 Chaperone Complex
    Rachel E. Hayward, Raymond F. Berkeley, Zijian Gao, Maximilian Garhammer, Marc A. Morizono, Evert Njomen, Haoxin Li, Kristen E. DeMeester, Victor Cociorva, Mark A. Herzik et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Design and synthesis of inhibitors of foot-and-mouth disease virus 3C protease
    Nicholas E. Milton · 2014 · Spiral (Imperial College London)
  47. Probe Report for RBBP9 Inhibitors - Probe 2
    DA Bachovchin, AE Speers, SJ Brown, BF Cravatt, Virneliz Fernández-Vega, Timothy P. Spicer, BA Mercer, J Ferguson, Peter Hodder, HR Rosen · 2010 · Europe PMC (PubMed Central)
  48. The Characterization of the Novel Chloroquine Derivative VR23 for its Anticancer Properties
    Sheetal Pundir · 2015 · uO Research (University of Ottawa)
  49. Computational Investigation into Catalytic Mechanisms of Disease-Causing Enzymes and Biocatalysts
    Corey A. MacDonald · 2015
  50. "The journal's editorial team places strong emphasis on reaching out to our readership and contributors as part of a sustained effort to ensure the journal continues to reflect the interests and concerns of the community. "
    Gino D’Oca · 2013
  51. Optimization and Characterization of an Inhibitor for Glutathione S-Tranferase Omega 1 (GSTO1)
    Katsunori Tsuboi, Daniel A. Bachovchin, Anna E Speers, Steven J Brown, Timothy Spicer, Virneliz Fernández-Vega, Jill Ferguson, Benjamin F. Cravatt, Peter Hodder, Hugh Rosen · 2011 · Europe PMC (PubMed Central)
  52. Discovery and characterization of synthetic and natural compounds as inhibitors of shikimate kinase from Mycobacterium tuberculosis by LC-MS
    Johayra Simithy · 2014
  53. Light-activated Binary Nucleotide Reagent For Inactivation Of Dna Polymerase
    Evan M. Cornett · 2012 · Journal of International Crisis and Risk Communication Research
  54. Physicochemical properties of isolated biomolecule clusters
    Ahdia Anwar · 2017 · UWSpace (University of Waterloo)
  55. Discovery and elucidation of unknown protein modifications : brominated coumarin azide as a probe for alkynes
    Yang Yang · 2017
  56. Baccalaureate and Higher Degree Program's Accreditation Committee reports on evaluation data.
    C M Schultz, Linda Niedringhaus · 1995 · PubMed
  57. Coupling of HSP72 α-Helix Subdomains by the Unexpected Irreversible Targeting of Lysine-56 over Cysteine-17; Coevolution of Covalent Bonding
    Aimen Aljoundi, Ahmed Abd Elkader El-Rashedy, Patrick Appiah‐Kubi, Mahmoud E. S. Soliman · 2020 · Molecules
  58. Modulating the Reactivity of Electrophilic Warheads for Pharmacokinetic Efficacy
    Mariya Bogatchenko · 2018 · TSpace (University of Toronto)
  59. Use of Structure-And Ligand-Based Drug Design Tools for the Discovery of Small Molecule Inhibitors of Cysteine Proteases for the Treatment of Malaria and Sars Infection
    Falgun Shah · 2011
  60. JAK Family Inhibitors for Autoimmune Diseases
    R. M. Borzilleri, Amy C. Hart, Ryan M. Moslin, John S. Tokarski, Stephen T. Wrobleski · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  61. Docking Ligands into Flexible and Solvated Macromolecules. 8. Forming New Bonds – Challenges and Opportunities.
    Nicolas Moitessier, Anne Labarre, Julia K. Stille, Mihai Burai Patrascu, Andrew Martins, Joshua Pottel · 2021 · ChemRxiv
  62. Therapy in pipeline for age-related macular degeneration
    Weiye Li · 2021 · Elsevier eBooks
  63. Redirecting the Cellular Waste Disposal Machinery to Target Transcription
    Helen H. Yu, Kathleen M. Sakamoto · 2021 · Springer eBooks
  64. Inhibition studies on the human 20S proteasome: molecular insights from a computational approach
    Natalia Serrano-Aparicio · 2022
  65. Fisiología de la resistencia múltiple a los herbicidas glifosato e inhibidores de acetolactato sintasa en amaranthus palmeri
    María Barco-Antoñanzas · 2022
  66. Docking Ligands into Flexible and Solvated Macromolecules. 8. Forming New Bonds – Challenges and Opportunities.
    Nicolas Moitessier, Anne Labarre, Julia K. Stille, Mihai Burai Patrascu, Andrew Martins, Joshua Pottel · 2021 · ChemRxiv
  67. Docking Ligands into Flexible and Solvated Macromolecules. 8. Forming New Bonds – Challenges and Opportunities.
    Nicolas Moitessier, Anne Labarre, Julia K. Stille, Mihai Burai Patrascu, Andrew Martins, Joshua Pottel · 2021
  68. Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10‐2474
    Nuno M. F. S. A. Cerqueira, Marco Neves, Juliana F. Rocha, Patrício Soares‐da Silva, P. Nuno Palma · 2022 · ChemBioChem
  69. A kovalens enziminhibíció számításos kémiai jellemzése
    Levente M. Mihalovits, György G. Ferenczy, György Miklós Keserű · 2022 · Magyar kémiai folyóirat, Kémiai közlemények
  70. Covalent Modification of Proteins by Osthole Reactive Metabolites using Proteomic Approaches
    Yue Zhuo, Huiling Chen, Chenchen Liu, Yida Zhang, Jiansong Fang, Meng Li, Zhendong Wang, Qiyao Jiang, Liangwen Yu, Huafeng Pan et al. · 2023 · Current Drug Metabolism
  71. In Vitro Biology: Measuring Pharmacological Activity that Will Translate to Clinical Efficacy
    Iain G. Dougall, Rachel L. Grimley, Per-Erik Strömstedt · 2023 · Royal Society of Chemistry eBooks
  72. Comparative study of covalent & non-covalent drug inhibitory mechanism investigation: targeting HSP72 protein in cancer therapy using molecular modelling techniques.
    Aimen Aljoundi · 2021
  73. Ultrasound Guided Local Delivery of Bioorthogonal PDL1 Degrader for Enhanced Immunotherapy
    Lantian Wang, Zhaoyou Liu, Panpan Ji, Jiao Ma, Ke Mou, Tian Zhou, Yuan Liang, Bin Zhang, Mengying Wei, Guodong Yang et al. · 2024 · Small
  74. Click Chemistry for Target Engagement Studies
    Silvia Castelli, Sonia Troiani, Ulisse Cucchi · 2025 · Methods in molecular biology
  75. Novel glycine amides, semicarbazides and fluoroallylamines as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1)
    Timo Pöstges, Jan Kampschulze, Walburga Hanekamp, Marcel Bermúdez, Matthias Lehr · 2026 · RSC Medicinal Chemistry
  76. Application of a MALDI mass spectrometry assay to identify covalent fragments targeting the methyl-lysine reader protein MPP8
    Juanita Sanchez Rubiano, Peter H. Buttery, Zachary A. Gurard‐Levin, Jacqueline L. Norris-Drouin, Lilyan M. Mather, P. Brian Hardy, Stephen V. Frye, Lindsey Ingerman James · 2026 · SLAS DISCOVERY
  77. Discovery and characterization of a covalent inhibitor of New Delhi metallo β-lactamase
    Dann D. Rivera, John M. Schroeder, Jada N. Walker, Aarti Bashyal, Ayush G. Iyer, Ryan H. Lee, Trevor R. Melkonian, Jennifer S. Brodbelt, Walter L Fast, Christian P. Whitman · 2026 · Archives of Biochemistry and Biophysics
  78. Modulateurs synthétiques de la kallikréine 6, protéase à sérine impliquée dans les maladies neurodégénératives : identification, mécanisme d’action et validation de concept
    Feryel Soualmia · 2016
  79. Research on the Mechanism of Covalent Interactions in Targeted Drug Design
    Wentao Liu · 2026 · Highlights in Science Engineering and Technology
  80. Targeting kinases in neurodegenerative diseases and cancer: Structural insights and therapeutic strategies
    Anas Shamsi, Saleha Anwar, Khuzin Dinislam · 2026 · Advances in protein chemistry and structural biology
  81. Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation
    Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Corrêa Veríssimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael V. C. Guido, Anthony John O’Donoghue et al. · 2026 · ChemMedChem
  82. A decision-driven framework for the mass spectrometry analysis of previously uncharacterized protein modifications
    Yiying Zhu · 2026 · STAR Protocols
  83. L-arginine-Provoked Unfolding of Invertase and Its Refolding Facilitated by Natural Polysaccharides
    Biao Wang, Panpan Chen, Lei Wang, Meng-ling Qiu, Shuai Yan, Yu-Long Sun, Mian Li, Zhong‐Xiu Chen · 2026 · SSRN Electronic Journal
  84. Latest developments in small molecule inhibitors of cysteine protease B as antileishmanial drugs
    Karla Joane da Silva Menezes, Sonaly Lima Albino, João Vitor Vieira da Silva, Éric de Oliveira Rios, Rafaella Alves da Silva Barbosa, Juan David Rodríguez Macías, Edgar Márquez, Fátima Nogueira, Sofia Cortes, Ricardo Olímpio de Moura et al. · 2026 · Future Medicinal Chemistry
  85. Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches
    Phumelele Nodola, Patience Snenhlanhla Sthembile. Molefe, Potlaki Foster Tseki, Njabulo Joyfull Gumede · 2026 · Molecules
  86. High‐Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives
    Haipeng Yu, Xiaoran Wang, Xinyu Wang, Yizhen Yin · 2026 · Chemistry - A European Journal
  87. Bridging the Gap between Discovery and Clinical Reality in Radiopharmaceuticals: A Translational Science Perspective on Safety, Efficacy, and Manufacturability
    Xiaonan Kuang, Liang Zhang, Juan Tian, Ran Zhang, Yan Zhang, Longlong Luo · 2026 · Journal of Medicinal Chemistry
  88. Brief encounters and lasting impressions—How target protein half‐life affects reactive metabolite signaling
    Marcus J.C. Long, Lorna Birkby, Yimon Aye · 2026 · FEBS Journal
  89. BindingDB Entry 50039358: Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
    BindingDB · 2013 · UC San Diego
  90. BindingDB Entry 50045738: Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors.
    BindingDB · 2016 · UC San Diego
  91. BindingDB Entry 50021382: Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor.
    BindingDB · 2025 · UC San Diego
  92. BindingDB Entry 50017017: Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site.
    BindingDB · 2023 · UC San Diego
  93. BindingDB Entry 50005631: Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
    BindingDB · 2020 · UC San Diego
  94. BindingDB Entry 50003230: Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.
    BindingDB · 2020 · UC San Diego
  95. BindingDB Entry 50001481: Identification of the Histidine Residue in Vitamin D Receptor That Covalently Binds to Electrophilic Ligands.
    BindingDB · 2020 · UC San Diego
  96. BindingDB Entry 50001052: Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
    BindingDB · 2020 · UC San Diego
  97. BindingDB Entry 50044783: Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
    BindingDB · 2016 · UC San Diego
  98. BindingDB Entry 50009366: Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
    BindingDB · 2021 · UC San Diego
  99. BindingDB Entry 50015923: Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
    BindingDB · 2023 · UC San Diego
  100. BindingDB Entry 50000297: Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    BindingDB · 2019 · UC San Diego